Volume 29, Issue 2 (6-2005)                   Research in Medicine 2005, 29(2): 147-151 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Add-on therapy with topiramate in drug-resistant epilepsy. Research in Medicine. 2005; 29 (2) :147-151
URL: http://pejouhesh.sbmu.ac.ir/article-1-138-en.html
Abstract:   (15551 Views)

Background therapy. The present study was conducted to evaluate the efficacy and side effects of topiramate as an add-on therapy in drug-resistant ( intractable) epilepsies .

 Materials and methods hospital with refractory epilepsy were enrolled. The study population included 14 girls and 28 boys, aged 1-15 years. Seizure attacks were not controlled despite receiving 4-13 drugs (mean 9). Topiramate was added to the patient's drug in a 4-week titration regimen (1 st week 3, 2 nd week 5, 3 rd week 7, and 4 th week 9mg/kg). Then , after 3 months he/she was reevaluated .

 Results progressive myoclonic epilepsy were revealed in 14 (34%), 8(19%), 16(38%), and 4(9%), respectively . After the 3-month add-on therapy with topiramate, 17% became seizure-free and the frequency of seizure attacks decreased by 50% in 26% of the patients , however, attacks were exacerbated in 5%. Fortunately, hematologic, renal or hepatic side effects were not reported, however, mild transient neurologic complications were observed in 12% of the patients .

 Conclusion intractable seizures

Full-Text [PDF 118 kb]   (3037 Downloads)    
Type of Study: General | Subject: Interdisciplinary (Educational Management, Educational research, Statistics, Medical education
Received: 2003/11/28 | Published: 2005/06/15

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This Journal is licensed under a Creative Commons Attribution 4.0 International License  | Research in Medicine

Designed & Developed by : Yektaweb